Paper39384682
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.
Boattini M and 4 others. Eur J Clin Microbiol Infect Dis, 2024. Cited by 23 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series. Papers, record 39384682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39384682
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Azabicyclo Compounds | Major topic |
| beta-Lactamase Inhibitors | Major topic |
| beta-Lactamases | Major topic |
| Drug Combinations | Major topic |
| Klebsiella Infections | Major topic |
| Klebsiella pneumoniae | Major topic |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Bacterial Proteins | |
| Ceftazidime | |
| Drug Resistance, Multiple, Bacterial | |
| Microbial Sensitivity Tests | |
| Retrospective Studies | |
| Whole Genome Sequencing |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35,139,426 | Outbreak of ceftazidime-avibactam resistant Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in a COVID-19 intensive care unit, Italy: urgent need for updated diagnostic protocols of surveillance cultures. | J Hosp Infect | 2022 | https://conductscience.org/library/papers/35139426 | PubMed |
| 2 | 36,968,952 | Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21). | JAC Antimicrob Resist | 2023 | https://conductscience.org/library/papers/36968952 | PubMed |
| 3 | 36,716,999 | Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients. | Clin Microbiol Infect | 2023 | https://conductscience.org/library/papers/36716999 | PubMed |
| 4 | 35,187,577 | Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/35187577 | PubMed |
| 5 | 34,066,420 | Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018. | Antibiotics (Basel) | 2021 | https://conductscience.org/library/papers/34066420 | PubMed |
| 6 | 30,471,402 | In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. | Int J Antimicrob Agents | 2019 | https://conductscience.org/library/papers/30471402 | PubMed |
| 7 | 33,618,353 | Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33618353 | PubMed |
| 8 | 33,915,286 | Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect. | Clin Microbiol Infect | 2021 | https://conductscience.org/library/papers/33915286 | PubMed |
| 9 | 37,237,722 | Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/37237722 | PubMed |
| 10 | 36,154,170 | In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36154170 | PubMed |
| 11 | 33,895,414 | Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. | J Glob Antimicrob Resist | 2021 | https://conductscience.org/library/papers/33895414 | PubMed |
| 12 | 31,342,772 | Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update. | Ann Pharmacother | 2020 | https://conductscience.org/library/papers/31342772 | PubMed |
| 13 | 33,558,042 | Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series. | J Infect Chemother | 2021 | https://conductscience.org/library/papers/33558042 | PubMed |
| 14 | 36,414,199 | Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. | Clin Microbiol Infect | 2023 | https://conductscience.org/library/papers/36414199 | PubMed |
| 15 | 36,655,779 | Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. | Expert Rev Anti Infect Ther | 2023 | https://conductscience.org/library/papers/36655779 | PubMed |
| 16 | 19,015,357 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19015357 | PubMed |
| 17 | 37,985,552 | Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022). | Eur J Clin Microbiol Infect Dis | 2024 | https://conductscience.org/library/papers/37985552 | PubMed |
| 18 | 34,462,816 | In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects. | Eur J Clin Microbiol Infect Dis | 2022 | https://conductscience.org/library/papers/34462816 | PubMed |
| 19 | 35,416,711 | Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35416711 | PubMed |
| 20 | 31,400,759 | RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. | Clin Infect Dis | 2020 | https://conductscience.org/library/papers/31400759 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,967,154 | Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms-a narrative review for an enablement strategy. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42967154 | PubMed |
| 42,709,211 | Caerin 1.1/1.9 Inhibits Growth and Biofilm Formation of Carbapenem-Resistant Klebsiella pneumoniae and Induces Coordinated Transcriptomic Stress Responses. | Curr Microbiol | 2026 | https://conductscience.org/library/papers/42709211 | PubMed |
| 42,558,781 | Emergence of carbapenemase KPC-14 in an Escherichia coli isolate: a case report. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42558781 | PubMed |
| 42,376,570 | Genomic characterization of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in bloodstream infections indicates OmpK35 and OmpK36 as pivotal key players in resistance mechanisms. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42376570 | PubMed |
| 42,137,798 | Rapid and high-sensitivity quantitative fluorescent immunoassay for detection of Klebsiella pneumoniae carbapenemase. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42137798 | PubMed |
| 41,892,432 | Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892432 | PubMed |
| 41,608,681 | Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. | Front Microbiol | 2025 | https://conductscience.org/library/papers/41608681 | PubMed |
| 41,436,714 | Emergence of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae: clinical and genomic insights from consecutive bloodstream infections. | Infection | 2026 | https://conductscience.org/library/papers/41436714 | PubMed |
| 41,214,240 | In vivo evolution of resistance to novel β-lactam/β-lactamase inhibitor combinations through overproduction of the horizontally acquired extended-spectrum AmpC β-lactamase FOX-14 and porin disruption in Serratia marcescens. | Eur J Clin Microbiol Infect Dis | 2026 | https://conductscience.org/library/papers/41214240 | PubMed |
| 41,105,373 | Impact of ompK35 and ompK36 downregulation on antibiotic resistance in clinical carbapenem-resistant Klebsiella pneumoniae isolates. | Folia Microbiol (Praha) | 2025 | https://conductscience.org/library/papers/41105373 | PubMed |
| 40,926,214 | Epidemiology, resistance profiles, and risk factors of multidrug- and carbapenem-resistant Serratia marcescens infections: a retrospective study of 242 cases. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/40926214 | PubMed |
| 40,600,143 | Identification of two KPC variants, KPC-204 and KPC-227, in ST11-K64 Klebsiella pneumoniae during prolonged hospitalization of a single patient. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40600143 | PubMed |
| 40,521,716 | Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023). | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/40521716 | PubMed |
| 40,251,649 | Clinical and Microbiological characteristics of patients with ceftazidime/avibactam-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains. | Ann Clin Microbiol Antimicrob | 2025 | https://conductscience.org/library/papers/40251649 | PubMed |
| 39,727,974 | Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39727974 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39384682
GET https://conductscience.org/api/papers/v1/39384682/references?page=2